<unk>  has black box warnings in the United States for increased risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access, and tumor progression or recurrence. To avoid side effects, it is recommended for patients with chronic kidney failure or cancer to use the lowest possible dose needed to avoid red blood cell (RBC) transfusions. In addition to those listed in the black box warning, use of<unk>  also increases the risk of cardiovascular problems, including cardiac arrest, arrhythmia, hypertension and congestive heart failure, and edema. A recent study has extended these findings to treatment of patients exhibiting cancer-related anemia (distinct from anemia resulting from chemotherapy). Other reported adverse reactions include increased risk of seizure, hypotension, and chest pain.
Darbepoetin alfa
Lipegfilgrastim
Pegfilgrastim
Filgrastim
Vorinostat
Asciminib
Etalocib
EPOCH 